L3VLUP
ProSign in

ABCL · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ABCLVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ABCL
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterABCLVRTX
Q3 2020none listed holders, n.a.31 holders, $21.9bn
Q4 20204 holders, $960m30 holders, $18.4bn
Q1 20214 holders, $837m31 holders, $15.4bn
Q2 20213 holders, $364m30 holders, $12.7bn
Q3 20213 holders, $470m35 holders, $10.1bn
Q4 20213 holders, $376m28 holders, $12.4bn
Q1 20223 holders, $287m23 holders, $16.1bn
Q2 20225 holders, $326m25 holders, $18.1bn
Q3 20227 holders, $270m22 holders, $18.4bn
Q4 20223 holders, $294m28 holders, $18.4bn
Q1 20234 holders, $221m26 holders, $21.4bn
Q2 20234 holders, $226m27 holders, $24.7bn
Q3 20233 holders, $160m33 holders, $24.3bn
Q4 20233 holders, $186m32 holders, $28.6bn
Q1 20243 holders, $144m31 holders, $29.8bn
Q2 20243 holders, $81m29 holders, $33.4bn
Q3 20241 holders, $34m27 holders, $33.5bn
Q4 20242 holders, $59m26 holders, $28.5bn
Q1 20252 holders, $55m21 holders, $35.4bn
Q2 20253 holders, $95m21 holders, $32.3bn
Q3 20255 holders, $147m22 holders, $25.9bn
Q4 20253 holders, $63m26 holders, $31.8bn
Q1 20261 holders, $47m25 holders, $31.8bn
Q2 20262 holders, $189m26 holders, $34.6bn
ABCL

Abcellera Biologics Inc

Holders
2
Reported value
$189m
Buyers
12
Sellers
13

Breadth -1 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
26
Reported value
$34.6bn
Buyers
21
Sellers
17

Breadth +4 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2026

Among the 26 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ABCL (0)

None.

Only VRTX (24)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Baillie Gifford & Co, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Citadel Advisors LLC, Fidelity (FMR LLC), Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →